Mar 15 • 16:52 UTC 🇦🇷 Argentina Clarin (ES)

Chiqui Tapia lamented the cancellation of the Finalissima and stated that the AFA had accepted to play it in Italy, but with a different date

Claudio 'Chiqui' Tapia expressed disappointment over the cancellation of the Finalissima and clarified that the AFA was open to rescheduling the match in Italy.

Claudio 'Chiqui' Tapia, the president of the Argentine Football Association (AFA), expressed his disappointment regarding the cancellation of the highly anticipated Finalissima match between Argentina and Spain. In a statement shared on social media, Tapia highlighted that the AFA was willing to host the match in Italy, but at a different date than initially proposed by UEFA. His comments were a direct response to UEFA's earlier harsh statement alleging that Argentina had rejected rescheduling proposals, particularly in light of the change of venue due to the ongoing conflict in the Middle East.

In the wake of the cancellation, Tapia reiterated the AFA's long-held position that the match needed to be held at a neutral venue to ensure fair competition. He specifically noted that the initial suggestion of playing the match in Madrid was not communicated to the AFA properly, as they only learned about it through media reports. This raises further questions about the communication and negotiations between UEFA and the South American football governing body, Conmebol, which supported Tapia's statements.

The implications of this situation extend beyond just the immediate disappointment over the match cancellation; they also highlight ongoing geopolitical tensions impacting international sports scheduling. With the match initially set to take place in Qatar now canceled, concerns arise regarding how similar circumstances might affect future international fixtures and the logistics behind organizing them amidst global conflict. Such instances call into question the stability and reliability of future international sporting events, particularly in regions prone to unrest.

📡 Similar Coverage